News today:
Monday November 2, 8:07 am Eastern Time
Company Press Release
SOURCE: Endocare, Inc.
Long Term Data Revealed on Endocare's Prostate Cancer Treatment at
10th World Congress of Cryosurgery
Initial Five Year Data Announced Before International Forum
ORLANDO, Fla., Nov. 2 /PRNewswire/ -- Long term data on the success of targeted cryoablation procedures for prostate cancer was presented this weekend at
the 10th Annual Congress on Cryosurgery. The results point toward temperature monitored ''freezing'' of cancerous tissue utilizing technology developed by
Endocare, as a viable, minimally invasive method of successfully ridding the body of cancer.
Before an audience of the world's leading clinicians and scientists from an array of international centers of excellence, Douglas Chinn, M.D. of southern California's
Alhambra Hospital, revealed newly compiled compelling 5-year data on cryoablation procedures utilizing state of the art temperature monitoring. The data was
highlighted by the announcement that more than 8 out of ten of Dr. Chinn's and Dr. Wilson Wong's patients who received monitored temperature-based treatment
for prostate cancer over the past five years remain cancer-free (as determined by negative biopsy results).
In addition, Chinn announced that the PSA rates among patients receiving temperature monitored treatment were undetectable and that the incontinence rate was
less than 2%.
Chinn's and Wong's data comes on the heels of similarly successful results for the same procedure reported recently by Fred Lee, M.D., and Duke Bahn, M.D., of
Crittenton Hospital in Rochester, Michigan. Lee's and Bahn's newly compiled four-year data on results for targeted cryoablation illustrate an 85% success rate. Lee,
who was also present at the Congress, reported that more than 580 of his patients remain cancer-free and over 98% of the patients required only an overnight stay
at the hospital following their cryoablation treatment.
''Targeted cryoablation is the best treatment methodology available for men with prostate cancer,'' said Lee, ''and I've seen them all. I say this not only as a doctor
utilizing the technology to treat patients, but as a prostate cancer survivor myself.''
The technology currently used by Dr.'s Chinn, Wong and Lee was developed by Irvine, California based Endocare, Inc. (Nasdaq: ENDO - news). The company
develops, manufactures and markets an array of innovative, temperature-based surgical devices and technologies, including devices used to treat prostate cancer
and cancer of the liver. The company is also developing an innovative stent technology for prostate obstruction.
Cancer of the prostate is the second most common malignancy in men and the third most common cause of death. In the U.S., the disease afflicts approximately five
million men.
Any statements in this release that are not historical facts are forward-looking statements that involve risks and uncertainties; actual results may differ from the
forward-looking statements. Words such as ''expect, suggest, may, believe, could, might, will, continue, should, planned, anticipated, designed'' indicate
forward-looking statements but their absences does not mean that a statement is not forward-looking. Factors that could materially and adversely impact revenues
and profitability are detailed from time to time in the Company's periodic reports, including Quarterly Reports on Form 10-Q, the Annual Report on Form 10-K
and the Registration Statement on Form S-3, filed with the Securities and Exchange Commissions. The Company undertakes no obligation to update
forward-looking statements.
SOURCE: Endocare, Inc.
>>>>>
-DavidCG |
